| Combination of | |
|---|---|
| Hydrocodone | Opioid agonist |
| Guaifenesin | Expectorant |
| Clinical data | |
| Trade names | Obredon, Flowtuss, others |
| AHFS/ Drugs.com | |
| License data | |
|
Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Hydrocodone/guaifenesin, sold under the brand name Obredon among others, is a fixed-dose combination medication used for the treatment of cough. [2] It contains hydrocodone, as the bitartrate, an opioid agonist; and guaifenesin, an expectorant. [2] It is taken by mouth. [2]
Hydrocodone/guaifenesin was approved for medical use in the United States in 2014. [3] [4]
Adverse effects
In the US, the label for hydrocodone/guaifenesin contains a black box warning about addiction, abuse, and misuse. [2]
References
- ^ "Flowtuss (hydrocodone bitartrate and guaifenesin) oral solution, CII Initial U.S. Approval: 2014". DailyMed. Retrieved 21 December 2023.
- ^ a b c d e "Obredon- hydrocodone bitartrate and guaifenesin solution". DailyMed. 15 December 2023. Retrieved 21 December 2023.
- ^ "Flowtuss, (hydrocodone bitartrate and guaifenesin), oral solution". U.S. Food and Drug Administration (FDA). 29 February 2016. Retrieved 21 December 2023.
- ^ "Obredon, (hydrocodone/guaifenesin) Oral Solution". U.S. Food and Drug Administration (FDA). 7 April 2015. Retrieved 21 December 2023.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
| Combination of | |
|---|---|
| Hydrocodone | Opioid agonist |
| Guaifenesin | Expectorant |
| Clinical data | |
| Trade names | Obredon, Flowtuss, others |
| AHFS/ Drugs.com | |
| License data | |
|
Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Hydrocodone/guaifenesin, sold under the brand name Obredon among others, is a fixed-dose combination medication used for the treatment of cough. [2] It contains hydrocodone, as the bitartrate, an opioid agonist; and guaifenesin, an expectorant. [2] It is taken by mouth. [2]
Hydrocodone/guaifenesin was approved for medical use in the United States in 2014. [3] [4]
Adverse effects
In the US, the label for hydrocodone/guaifenesin contains a black box warning about addiction, abuse, and misuse. [2]
References
- ^ "Flowtuss (hydrocodone bitartrate and guaifenesin) oral solution, CII Initial U.S. Approval: 2014". DailyMed. Retrieved 21 December 2023.
- ^ a b c d e "Obredon- hydrocodone bitartrate and guaifenesin solution". DailyMed. 15 December 2023. Retrieved 21 December 2023.
- ^ "Flowtuss, (hydrocodone bitartrate and guaifenesin), oral solution". U.S. Food and Drug Administration (FDA). 29 February 2016. Retrieved 21 December 2023.
- ^ "Obredon, (hydrocodone/guaifenesin) Oral Solution". U.S. Food and Drug Administration (FDA). 7 April 2015. Retrieved 21 December 2023.
|
| This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |